Deutsche Bank
PRME icon

Deutsche Bank’s Prime Medicine PRME Stock Holding History

Deutsche Bank’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$548K Buy
157,440
+9,497
+6% +$36.1K ﹤0.01% 2530
2025
Q4 		$513K Buy
147,943
+15,174
+11% +$67.5K ﹤0.01% 2555
2025
Q3 		$736K Buy
132,769
+7,324
+6% +$29.8K ﹤0.01% 2343
2025
Q2 		$310K Sell
125,445
-1,401
-1% -$2.16K ﹤0.01% 2714
2025
Q1 		$252K Buy
126,846
+46,011
+57% +$117K ﹤0.01% 2846
2024
Q4 		$236K Sell
80,835
-34,072
-30% -$120K ﹤0.01% 3023
2024
Q3 		$445K Sell
114,907
-346,088
-75% -$1.6M ﹤0.01% 2523
2024
Q2 		$2.37M Buy
460,995
+440,280
+2,125% +$2.67M ﹤0.01% 1558
2024
Q1 		$145K Buy
20,715
+614
+3% +$4.66K ﹤0.01% 3002
2023
Q4 		$178K Sell
20,101
-454
-2% -$3.5K ﹤0.01% 2941
2023
Q3 		$196K Buy
20,555
+2,743
+15% +$35.6K ﹤0.01% 2797
2023
Q2 		$261K Buy
17,812
+6,952
+64% +$97.1K ﹤0.01% 2734
2023
Q1 		$134K Buy
10,860
+6,387
+143% +$104K ﹤0.01% 3198
2022
Q4 		$83.1K Buy
+4,473
New +$80.8K ﹤0.01% 3413

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Deutsche Bank's PRME Position: Q1 2026 in Review

Deutsche Bank increased its Prime Medicine (PRME) stake by 6.4% in Q1 2026, buying an estimated $36.1K and bringing the position to 157,440 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

Deutsche Bank first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.37M in Q2 2024. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Deutsche Bank held 157,440 shares of Prime Medicine worth $548K as of Q1 2026.
  • Deutsche Bank bought 9,497 Prime Medicine shares in Q1 2026, an estimated $36.1K.
  • Prime Medicine made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2530 holding.
  • Deutsche Bank first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Deutsche Bank's Prime Medicine position peaked at $2.37M in Q2 2024.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.